You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Cassava Sciences Return vs. S&P
|5 Year Annualized
Cassava Sciences Company Info
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
News & Analysis
Is There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper.
Why Cassava Sciences Stock Zoomed 21% Higher This Week
The company has chosen an offbeat way to keep its investors sweet.
Why Cassava Sciences Stock Soared Today
Investors cheered the arrival of a trio of new board members.
1 Big Red Flag to Fear When a Stock Is Down
Playing the blame game does not make for an effective turnaround strategy.
Why Cassava Sciences Stock Is Tanking Today
Investors are worried about a leaked report related to alleged data manipulation for Cassava's Alzheimer's disease treatment candidate.
Why Shares of Cassava Sciences Soared This Week
Cassava bounced back from hitting a 52-week low to start the week.
Why Shares of Cassava Sciences Are Dropping Wednesday
The company announced phase 3 trial results for its lead Alzheimer's therapy.
Why Shares of Cassava Sciences Jumped This Week
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.